{
  "content": [
    {
      "type": "text",
      "text": "# Timeline of immunology\n\nThe following are notable events in the Timeline of immunology:\n* 1550 BCE – The Ebers papyrus recommends placing a poultice on a tumor and then making an incision, which would induce infection and cause regression of the tumor\n* 1549 – The earliest account of inoculation of smallpox (variolation) occurs in Wan Quan's (1499&ndash;1582) Douzhen Xinfa (痘疹心法)\n* 1718 – Smallpox inoculation in Ottoman Empire realized by West, and Henry Kipkosgei, recorded the positive effects of variolation\n* 1761 – A case of breast cancer cured after ulcerating and getting infected is reported by Lambergen\n* 1796 – First demonstration of smallpox vaccination (Edward Jenner)\n* 1808–1813 – First experimental demonstration of the germ theory of disease (Agostino Bassi, though he does not formally propose the theory until 1844)\n* 1813 – Vautier reports spontaneous remission of cancer after gangrene infection (later to be known as Clostridium perfringens)\n* 1829 – Another case of spontaneous remission of breast cancer after a patient refused surgery and the tumor ruptured, became infected and during a febrile illness with purulent discharge, it shrunk and disappeared after a few weeks. (Guillaume Dupuytren)\n* 1837 – Description of the role of microbes in putrefaction and fermentation (Theodore Schwann)\n* 1838 – Confirmation of the role of yeast in fermentation of sugar to alcohol (Charles Cagniard-Latour)\n* 1850 – Demonstration of the contagious nature of puerperal fever (childbed fever) (Ignaz Semmelweis)\n* 1857–1870 – Confirmation of the role of microbes in fermentation (Louis Pasteur)\n* 1862 – Phagocytosis (Ernst Haeckel)\n* 1863 – Mast cells (Friedrich von Recklinghausen)\n* 1867 – Aseptic practice in surgery using carbolic acid (Joseph Lister)\n* 1868 – Busch discovered that a sarcoma patient being surgically intervened to remove the tumor, after being exposed to a patient suffering from erysipelas, got a skin infection and her tumor disappeared. He inoculated some other cancer patients with many successes\n* 1876 – Demonstration that microbes can cause disease-anthrax (Robert Koch)\n* 1878 – Confirmation and popularization of the germ theory of disease (Louis Pasteur)\n* 1880 – 81 Theory that bacterial virulence could be attenuated by culture in vitro and used as vaccines. Used to make chicken cholera and anthrax \"vaccines\" (Louis Pasteur)\n* 1882 – Identification of Streptococcus pyogenes as the causative agent of erysipelas (Friedrich Fehleisen). He repeats Busch experiments inoculating cancer patients with eryisipelas, noting tumor regression in many of them\n* 1883–1905 – Cellular theory of immunity via phagocytosis by macrophages and microphages (polymorhonuclear leukocytes) (Elie Metchnikoff)\n* 1885 – Introduction of concept of a \"therapeutic vaccination\". Report of a live \"attenuated\" vaccine for rabies (Louis Pasteur and Pierre Paul Émile Roux)\n* 1888 – Identification of bacterial toxins (diphtheria bacillus) (Pierre Roux and Alexandre Yersin)\n* 1888 – Bactericidal action of blood (George Nuttall)\n* 1890 – Demonstration of antibody activity against diphtheria and tetanus toxins. Beginning of humoral theory of immunity. (Emil von Behring) and (Kitasato Shibasaburō)\n* 1891 – Demonstration of cutaneous (delayed type) hypersensitivity (Robert Koch)\n* 1893 – Use of live bacteria and bacterial lysates to treat tumors – \"Coley's Toxins\", based on Busch and Fehleisen experiences (William B. Coley)\n* 1894 – Bacteriolysis (Richard Pfeiffer)\n* 1896 – An antibacterial, heat-labile serum component (complement) is described (Jules Bordet)\n* 1900 – Antibody formation theory (Paul Ehrlich)\n* 1901 – 1907 - Blood groups (Karl Landsteiner, Jan Janský)\n* 1902 – Immediate hypersensitivity anaphylaxis (Paul Portier) and (Charles Richet)\n* 1903 – Intermediate hypersensitivity, the \"Arthus reaction\" (Maurice Arthus)\n* 1903 – Opsonization\n* 1905 – \"Serum sickness\" allergy (Clemens von Pirquet and (Bela Schick)\n* 1909 – Paul Ehrlich proposes \"immune surveillance\" hypothesis of tumor recognition and eradication\n* 1911 – 2nd demonstration of filterable agent that caused tumors (Peyton Rous)\n* 1917 – Hapten (Karl Landsteiner)\n* 1921 – Cutaneous allergic reactions (Otto Prausnitz and Heinz Küstner)\n* 1924 – Reticuloendothelial system\n* 1925 – Adjuvants (Gaston Ramon)\n* 1938 – Antigen-Antibody binding hypothesis (John Marrack)\n* 1940 – Identification of the Rh antigens (Karl Landsteiner and Alexander Weiner)\n* 1942 – Anaphylaxis (Karl Landsteiner and Merill Chase)\n* 1944 – hypothesis of allograft rejection\n* 1945 – Coombs test  antiglobulin test (AGT)\n* 1946 – Identification of mouse MHC (H2) (George Snell and Peter A. Gorer)\n* 1948 – Antibody production in plasma B cells (Astrid Fagraeus)\n* 1949 – Growth of polio virus in tissue culture, neutralization, and demonstration of attenuation of neurovirulence (John Enders), (Thomas Weller) and (Frederick Robbins)\n* 1951 – A vaccine against yellow fever\n* 1953 – Graft-versus-host disease\n* 1953 – Validation of immunological tolerance hypothesis\n* 1957 – Clonal selection theory (Frank Macfarlane Burnet)\n* 1957 – Discovery of interferon (Alick Isaacs and Jean Lindenmann)\n* 1958–1962 – Discovery of human leukocyte antigens (Jean Dausset and others)\n* 1959–1962 – Discovery of antibody structure (independently elucidated by Gerald Edelman and Rodney Porter)\n* 1959 – Discovery of lymphocyte circulation (James Gowans)\n* 1960 – Discovery of lymphocyte \"blastogenic transformation\" and proliferation in response to mitogenic lectins-phytohemagglutinin (PHA) (Peter Nowell)\n* 1961–1962 Discovery of thymus involvement in cellular immunity (Jacques Miller)\n* 1960 – Radioimmunoassay – (Rosalyn Sussman Yalow)\n* 1961 – Demonstration that glucocorticoids inhibit PHA-induced lymphocyte proliferation (Peter Nowell)\n* 1963 – Development of the plaque assay for the enumeration of antibody-forming cells in vitro by Niels Jerne and Albert Nordin\n* 1963 – Gell and Coombs classification of hypersensitivity\n* 1964–1968 – T and B cell cooperation in immune response\n* 1965 – Discovery of lymphocyte mitogenic activity, \"blastogenic factor\" (Shinpei Kamakura) and (Louis Lowenstein), (J. Gordon) and (L.D. MacLean)\n* 1965 – Discovery of \"immune interferon\" (gamma interferon) (E.F. Wheelock)\n* 1965 – Secretory immunoglobulins\n* 1967 – Identification of IgE as the reaginic antibody (Kimishige Ishizaka)\n* 1968 – Passenger leukocytes identified as significant immunogens in allograft rejection (William L. Elkins and Ronald D. Guttmann)\n* 1969 – The lymphocyte cytolysis Cr51 release assay (Theodore Brunner and Jean-Charles Cerottini)\n* 1971 – ELISA is invented at Stockholm University (Peter Perlmann and Eva Engvall)\n* 1972 – Structure of the antibody molecule\n* 1972 – Discovery of invertebrate immunity (Hans G. Boman)\n* 1973 – Dendritic Cells first described (Ralph M. Steinman)\n* 1974 – Immune Network Hypothesis (Niels Jerne)\n* 1974 – T-cell restriction to MHC (Rolf Zinkernagel and Peter C. Doherty)\n* 1975 – Generation of monoclonal antibodies (Georges Köhler and César Milstein)\n* 1975 – Discovery of Natural Killer cells (Rolf Kiessling, Eva Klein, Hans Wigzell)\n* 1976 – Identification of somatic recombination of immunoglobulin genes (Susumu Tonegawa)\n* 1980–1983 – Discovery and characterization of interleukins, 1 and 2 IL-1 IL-2 (Robert Gallo, Kendall A. Smith, Tadatsugu Taniguchi)\n* 1981 – First description of an animal antimicrobial peptide in Cecropia silk moths\n* 1983 – Discovery of the T cell antigen receptor TCR (Ellis Reinherz) (Philippa Marrack and John Kappler), (James Allison)\n* 1983 – Discovery of HIV (Luc Montagnier, Françoise Barré-Sinoussi and Robert Gallo)\n* 1985–1987 – Identification of genes for the T cell receptor\n* 1986 – Hepatitis B vaccine produced by genetic engineering\n* 1986 – Th1 vs Th2 model of T helper cell function (Timothy Mosmann)\n* 1988 – Discovery of biochemical initiators of T-cell activation: CD4- and CD8-p56lck complexes (Christopher E. Rudd)\n* 1990 – Gene therapy for SCID\n* 1991 – Role of peptide for MHC Class II structure (Scheherazade Sadegh-Nasseri & Ronald N. Germain)\n* 1992 – Discovery of transitional B cells (David Allman & Michael Cancro)\n* 1994 – Danger model of immunological tolerance is described by Polly Matzinger at the NIH\n* 1995 – First description of the function of the critical immune checkpoint CTLA-4 (James P. Allison)\n* 1995 – Regulatory T cells (Shimon Sakaguchi)\n* 1995 – First Dendritic cell vaccine trial reported (Mukherji et al.)\n* 1995 – Discovery of the insect Imd NF-κB pathway\n* 1996–1998 – Identification of Toll-like receptors as immune-regulating molecules\n* 1997 – Discovery of the autoimmune regulator and the AIRE gene\n* 2000 – Characterization of M1 and M2 macrophage subsets (Charles Mills)\n* 2001 – Discovery of FOXP3 – the gene directing regulatory T cell development\n* 2005 – Development of human papillomavirus vaccine (Ian Frazer)\n* 2006 – Antigen-specific NK cell memory first reported by Ulrich von Andrian's group after discovery by Mahmoud Goodarzi\n* 2010 – The first autologous cell-based cancer vaccine, Provenge, is approved by the FDA for the treatment of metastatic, asymptomatic stage IV prostate cancer\n* 2010 – First immune checkpoint inhibitor, ipilimumab (anti-CTLA-4), is approved by the FDA for treatment of stage IV melanoma\n* 2011 – Carl H. June reports first successful use of CAR T-cells expressing the 4-1BB costimulatory signaling domain for the treatment of CD19+ malignancies\n* 2014 – A second class of immune checkpoint inhibitor (anti-PD-1) is approved by the FDA for the treatment of melanoma. Pembrolizumab and nivolumab are approved within months of each other\n* 2016 – The role of dendritic cell expressed CTLA-4 in Th immune polarization is first described\n* 2016 – A third class of immune checkpoint inhibitor, anti-PD-L1 (atezolizumab), is approved for the treatment of bladder cancer\n* 2017 – First autologous CAR T-cell therapy tisagenlecleucel approved for the treatment of pediatric B-ALL; second autologous CAR T-cell therapy axicabtagene ciloleucel (Yescarta) is approved\n* 2020 – The first mRNA vaccines (BNT162b2, mRNA-1273), are developed for SARS-CoV-2 infection; this new technology completed design, testing, and emergency approval in under one year\n* 2025 – After completing phase I clinical trials in 2024 dubodencel, an autologous personalized dendritic cell vaccine platform, enters randomized trials for the treatment of newly-diagnosed glioblastoma\nReferences"
    }
  ]
}